PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Trial Profile

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 May 2018

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms PARTHENON
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 May 2018 Planned End Date changed from 1 May 2021 to 12 Oct 2020.
    • 23 May 2018 Planned primary completion date changed from 1 May 2021 to 12 Oct 2020.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top